Top Page
Elixinol Wellness
(OTC:EXL)
Elixinol Wellness (EXL) vs. iShares MSCI Australia ETF (EWA)
Elixinol Wellness Business Overview & Revenue Model
Elixinol Wellness Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.96M | 8.27M | 7.05M | 9.34M | 15.01M |
| Gross Profit | 5.36M | 3.27M | -3.27M | -6.25M | -9.58M |
| EBITDA | -4.06M | -6.81M | -9.28M | -15.51M | -23.36M |
| Net Income | -1.72M | -7.51M | -10.57M | -17.02M | -104.51M |
Balance Sheet | |||||
| Total Assets | 18.45M | 11.71M | 13.48M | 25.33M | 42.47M |
| Cash, Cash Equivalents and Short-Term Investments | 1.08M | 708.00K | 2.86M | 12.65M | 27.74M |
| Total Debt | 1.94M | 1.26M | 1.83M | 2.65M | 2.65M |
| Total Liabilities | 8.42M | 5.25M | 4.33M | 6.25M | 6.82M |
| Stockholders Equity | 10.03M | 6.46M | 9.16M | 19.08M | 35.65M |
Cash Flow | |||||
| Free Cash Flow | -3.53M | -2.77M | -8.16M | -14.36M | -22.95M |
| Operating Cash Flow | -3.47M | -2.76M | -8.15M | -14.07M | -22.62M |
| Investing Cash Flow | -66.00K | -1.04M | -869.00K | 172.00K | 2.55M |
| Financing Cash Flow | 3.92M | 1.61M | -757.00K | -1.16M | 27.55M |
Elixinol Wellness Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$3.91M | ― | -21.29% | ― | 80.87% | 82.44% | |
46 Neutral | C$197.02M | -3.33 | -23.14% | 2.65% | 20.75% | -0.36% | |
| ― | $6.77M | ― | -164.01% | ― | ― | ― | |
| ― | $4.74M | ― | -55.38% | ― | ― | ― | |
| ― | $4.69M | ― | ― | ― | ― | ||
53 Neutral | AU$23.85M | ― | -218.38% | ― | -14.30% | 29.69% | |
39 Underperform | AU$4.26M | ― | ― | ― | ― |
Elixinol Wellness Corporate Events
Elixinol Wellness Ltd announced a late lodgement of Appendix 3Y due to an administrative oversight related to a change in director’s interest. The company has acknowledged its obligations under ASX Listing Rules and has implemented measures to improve its internal processes to ensure future compliance, reflecting its commitment to transparency and regulatory adherence.
Elixinol Wellness Limited announced the quotation of 799,855 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of June 27, 2025. This move is part of their strategic financial operations, potentially enhancing their market presence and providing additional liquidity for stakeholders.
Elixinol Wellness Limited has announced significant executive leadership changes, appointing Natalie Butler as the new Chief Executive Officer and Adam Dimitropoulos as the Chief Financial Officer. These appointments are aimed at strengthening the company’s leadership team and positioning it for growth. Natalie Butler, who has been instrumental in leading the company through a complex period, is expected to drive the next phase of the company’s strategic priorities. Adam Dimitropoulos brings extensive financial and operational expertise, which will support Elixinol’s focus on delivering sustained profitability. The company acknowledges the contributions of outgoing CFO Josephine Lorenz and wishes her well in her future endeavors.
Elixinol Wellness Limited announced the cessation of 16,375,097 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s financial strategies and market positioning.
Elixinol Wellness Limited has announced a proposed non-pro rata offer of securities, planning to issue up to 100,000 ordinary fully paid shares. This move is part of the company’s strategy to raise capital, potentially impacting its market positioning and providing opportunities for investors to participate in the company’s growth.
Elixinol Wellness Limited has announced a prospectus for offering up to 100,000 new shares at an issue price of $0.1 per share, aiming to raise up to $10,000. This move is intended to remove trading restrictions on the sale of shares issued under this offer and prior to the prospectus date. The offer is considered speculative, and potential investors are advised to seek professional advice due to associated risks. The prospectus is not for distribution in the United States and is subject to legal restrictions in other jurisdictions.
Elixinol Wellness Limited announced the quotation of 8,571,429 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, potentially enhancing the company’s market presence and providing additional capital for its operations, which could have positive implications for its stakeholders.
Elixinol Wellness Limited, a company listed on the ASX, has announced that the suspension of its securities trading will be lifted following a new financing and capital arrangement. This development is expected to impact the company’s operations positively by resuming trading, potentially enhancing its market position and providing clarity to stakeholders.
Elixinol Wellness Limited has announced a proposed issue of 8,571,429 ordinary fully paid securities, set to be issued on May 28, 2025. This strategic move is aimed at enhancing the company’s financial flexibility and supporting its growth initiatives, potentially strengthening its position in the wellness market.
Elixinol Wellness Ltd has successfully raised $1.5 million through a combination of debt and equity to enhance its operational capabilities. The funds will be used to build inventory for its brands, automate manufacturing processes, and drive brand growth, positioning the company for improved margins and revenue growth. This strategic move is expected to strengthen Elixinol’s market position and operational efficiency, benefiting stakeholders and aligning with its growth objectives.
Elixinol Wellness Ltd announced the results of its Annual General Meeting, where all resolutions were carried, including the adoption of the remuneration report, re-election of a director, renewal of the equity plan, and approval of an additional placement capacity. These outcomes reflect shareholder support and may enhance the company’s strategic flexibility and governance structure.
Elixinol Wellness held its FY24 Annual General Meeting, providing general information about the company’s operations and investment risks. The presentation emphasized that it is not an investment recommendation and highlighted the uncertainties associated with forward-looking statements, urging investors to seek independent advice.
Elixinol Wellness has made significant progress in 2024, achieving an 81% increase in group revenue to $15 million, driven by strategic acquisitions and operational efficiencies. The company plans to continue its growth trajectory in 2025 by focusing on execution, scaling operations, and expanding its product offerings, particularly in the e-commerce and healthy snacking sectors, to enhance profitability and market reach.
Elixinol Wellness Ltd announced an extension of the voluntary suspension of its securities until May 21, 2025, due to the need for additional time to finalize ASX approval for its capital raising structure. This extension indicates ongoing efforts to secure financial stability and may impact the company’s market operations and stakeholder confidence.
Elixinol Wellness Limited, a company listed on the Australian Securities Exchange, has requested a voluntary suspension of its securities from trading. This suspension is pending an announcement regarding a potential financing or capital raising arrangement. The company aims to manage its continuous disclosure obligations effectively and expects to make the announcement before the commencement of normal trading on May 19, 2025.
Elixinol Wellness Limited, a company listed on the Australian Securities Exchange, has requested a trading halt on its securities. This pause in trading is due to an impending announcement regarding a potential financing or capital raising arrangement. The halt is expected to last until the company releases its announcement or until normal trading resumes on May 15, 2025. The move indicates a significant corporate development that could impact the company’s financial structure and market position.
Elixinol Wellness reported a 13.7% increase in revenue year-on-year for Q1 FY25, despite a decrease from the previous quarter due to timing delays and retail range rationalization. The company is undergoing structural realignment and cost-saving initiatives to strengthen its financial position, with new product launches and market expansions expected to drive growth in the latter half of 2025.
Elixinol Wellness Limited, a company listed on the ASX, has responded to a price query from the ASX regarding a recent drop in its securities’ price and a significant increase in trading volume. The company stated that it is not aware of any undisclosed information that could explain the recent trading activity and confirmed its compliance with ASX listing rules.